Giant Biogene (02367.HK): Leading Recombinant Collagen Player with Growth Prospects and Institutional Backing

Giant Biogene (02367.HK) is a China-based biotech firm specializing in recombinant collagen technology, with core brands KFM (medical repair) and KLW (anti-aging). It was the first in China to scale recombinant collagen skincare production [0].

The company has delivered consistent growth: 2022-2024 revenue rose from 23.64B to 55.4B RMB, with KFM contributing 82% of 2024 revenue [0]. 2025 H1 results showed 23% revenue growth and 20% net profit growth, with full-year guidance of 25-28% revenue and 21-24% net profit growth [0].

A first-in-China recombinant type I collagen lyophilized fiber product was approved, marking a new growth driver in medical aesthetics [0].

CMB International lowered the target price to 73.54 HKD but kept a ‘buy’ rating (sales recovery expectation) [3]. Citi raised its target to 69.4 HKD with a ‘buy’ rating [4]. Other institutions like Goldman Sachs and CICC maintain buy ratings (target range:69.4-73.54 HKD) [0].

Competition from peers like Huaxi Bio and product controversies are key risks [1]. High investor expectations for new consumer stocks mean short-term negative news could trigger sell-offs [2].